Cost-Effectiveness Analysis and the Formulary Decision-Making Process

Wang, Zhixiao; Salmon, J. Warren; Walton, Surrey M.

doi:10.18553/jmcp.2004.10.1.48

Cited by 17 publications

(11 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the year 2004 to 2005, an increase of 13.3% was recorded [1]. Factors that may contribute to this increase include increase in drug prices, a growing and aging population, higher expectation of the public regarding equality in assessing therapy, long‐term drug treatment and polypharmacy, improvements in diagnosis and treatment of diseases, and technological advancement that produces newer expensive drugs [2,3].…”

Section: Introductionmentioning

confidence: 99%

Drug Control and Formulary Management in Malaysia

Hussain

2008

Value in Health

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Drug Control and Formulary Management in Malaysia

Hussain

2008

Value in Health

View full text Add to dashboard Cite

“…These results suggest that treatment with aripiprazole tends to provide a valuable cost-offset in saving from decreased hospitalization risk and associated inpatient costs. In particular, the lower risk of hospitalization combined with lower total costs compared to quetiapine represent two attractive outcomes for formulary decision-makers responsible for the entire costs of care [22]. …”

Section: Discussionmentioning

confidence: 99%

One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis

et al. 2011

View full text Add to dashboard Cite

BackgroundThis study compared 1-year risk of psychiatric hospitalization and treatment costs in commercially insured patients with bipolar disorder, treated with aripiprazole, ziprasidone, olanzapine, quetiapine or risperidone.MethodsThis was a retrospective propensity score-matched cohort study using the Ingenix Lab/Rx integrated insurance claims dataset. Patients with bipolar disorder and 180 days of pre-index enrollment without antipsychotic exposure who received atypical antipsychotic agents were followed for up to 12 months following the initial antipsychotic prescription. The primary analysis used Cox proportional hazards regression to evaluate time-dependent risk of hospitalization, adjusting for age, sex and pre-index hospitalization. Generalized gamma regression compared post-index costs between treatment groups.ResultsCompared to aripiprazole, ziprasidone, olanzapine and quetiapine had higher risks for hospitalization (hazard ratio 1.96, 1.55 and 1.56, respectively; p < 0.05); risperidone had a numerically higher but not statistically different risk (hazard ratio 1.37; p = 0.10). Mental health treatment costs were significantly lower for aripiprazole compared with ziprasidone (p = 0.004) and quetiapine (p = 0.007), but not compared to olanzapine (p = 0.29) or risperidone (p = 0.80). Total healthcare costs were significantly lower for aripiprazole compared to quetiapine (p = 0.040) but not other comparators.ConclusionsIn commercially insured adults with bipolar disorder followed for 1 year after initiation of atypical antipsychotics, treatment with aripiprazole was associated with a lower risk of psychiatric hospitalization than ziprasidone, quetiapine, olanzapine and risperidone, although this did not reach significance with the latter. Aripiprazole was also associated with significantly lower total healthcare costs than quetiapine, but not the other comparators.

show abstract

“…1 Educational programs should enforce uniform drug use standards while maintaining quality initiatives. 10,11 When evaluating medications for formulary addition, a rigorous pharmacological and clinical review based on clinical trial and literature information is most valuable. Important elements of the review include general drug information, comparative drug efficacy, benefits and risks of therapy, pharmacoeconomics, monitoring, patient compliance issues, ease of physician acceptance, impact on various hospital departments, and needs of the institution.…”

Section: Health Care Team Approach To Iron Therapy Managementmentioning

confidence: 99%

Integrated Care of Anemia in Chronic Kidney Disease Patients: Concepts in Intravenous Iron Management: Part Two

et al. 2010

View full text Add to dashboard Cite

Iron deficiency anemia (IDA), as a result of chronic kidney disease (CKD), has become a worldwide public health issue with increasing prevalence in the United States. An awareness of clinical practice guidelines and safety profiles of intravenous (IV) iron products enables health care professionals to improve patient outcomes in the treatment of CKD-associated IDA. Selection of appropriate IV iron therapy in all patient care settings may encompass considerations such as product premedication and test-dose requirements, preparation and administration, monitoring parameters, safety concerns, cost of care, patient education, and patient self-administration when appropriate. More specifically, a medication use process (prescribing, preparing, dispensing, administering, monitoring, and specific outcomes) should be applied by health systems during the evaluation process to achieve optimal patient outcomes. This performance improvement process serves to promote appropriate medication therapy, improve patient safety, control costs of therapy, stimulate improvements in processes, and provide educational opportunities. This article, the second of a two-part series, describes elements of the medication use process for care of CKD patients with IDA, whereas the preceding article in this series discusses the optimization of IV iron therapy in CKD patients and compares the four parenteral iron agents available on the market.

show abstract

Cost-Effectiveness Analysis and the Formulary Decision-Making Process

Cited by 17 publications

References 43 publications

Drug Control and Formulary Management in Malaysia

Drug Control and Formulary Management in Malaysia

One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis

Integrated Care of Anemia in Chronic Kidney Disease Patients: Concepts in Intravenous Iron Management: Part Two

Contact Info

Product

Resources

About